ImageneBio, Inc. (IMA)

NASDAQ: IMA · USD

$4.30

+0.28 (+7.0%)· Recorded snapshot

Market cap	48.8M
Net income (ttm)	-53.3M
EPS (ttm)	-$4.81
Shares out	11.4M
Volume	21,697

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -53.3M
EPS (ttm): -$4.81
Market cap: 48.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-82.7

P25 -113.8P50 -46.5P75 -0.9

ROIC-48.4

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All IMA indicators

Market & fundamental data

Available fields

161

Groups with data

Currency

USD

Showing 161 of 161 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001835579
Company name	ImageneBio, Inc.
Country	United States
Country code	US
CUSIP number	45175G207
Earnings date	2026-11-11
Earnings time	bmo
Employees	18
Employees change	9
Employees growth	100%
Enterprise value	$-85.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2019
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US45175G2075
Last 10-K release date	2026-03-10
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$48.8M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	No
Price	$4.30
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	IMA
U.S. state	California
Website	https://www.inmagenebio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-111.94%
FCF / EV yield	59.35%
FCF yield	-115.24%
P/B ratio	0.32x
Price / tangible book value	0.32x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-3M
ROA	-43.06%
ROCE	-40.53%
ROE	-82.68%
ROIC	-48.44%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	1
Net income growth quarters	1
Net income growth years	0
Revenue growth	-77.14%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$594,500
EBIT	$-59M
EBITDA	$-58.4M
EPS	$-4.81
FCF per share	$-4.63
Financing cash flow	$147.2M
Free cash flow	$-52.6M
Free cash flow minus SBC	$-69.7M
Income taxes	$-324,000
Investing cash flow	$-6.6M
Net cash flow	$88.7M
Net income	$-53.3M
Operating cash flow minus SBC	$-69.7M
Operating income	$-59M
Stock-based compensation	$17.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.62
Book value per share	$12.60
Debt / equity	0.01
Long-term assets	$10.9M
Long-term liabilities	$3.4M
Net cash (debt)	$134.2M
Net cash / market cap	294.18%
Net debt / equity	-0.94
Piotroski F-Score	2
Property, plant and equipment	$521,000
Shareholders' equity	$142.1M
Tangible book value	$142.1M
Tangible book value per share	$12.60
Total assets	$152M
Total cash	$136.2M
Total debt	$1.9M
Total liabilities	$10M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$141.1M
Current liabilities	$6.6M
Current ratio	21.47
Net working capital	$298,000
Quick ratio	20.71
Working capital	$134.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	97.61%
Dividend yield	0%
Shareholder yield	97.61%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$5.36
1D price change	6.97%
1M price change	-12.29%
1M total return	-12.29%
1W price change	0.24%
1W total return	0.24%
1Y price change	-50.42%
1Y return CAGR	-50.44%
1Y total return	-50.42%
20-day SMA	$4.25
200-day SMA	$5.66
3M price change	-26.07%
3M total return	-26.07%
50-day SMA	$4.73
50-day SMA vs 200-day SMA	50under200
52-week high	$9.10
52-week high date	2025-10-29
52-week low	$3.88
52-week low date	2026-10-26
6M price change	-28.99%
6M total return	-28.99%
All-time high	$18.00
All-time high date	2025-07-28
All-time low	$3.88
All-time low date	2026-10-26
Average true range (ATR)	$0.25
Average volume	13.9K
Beta (1Y)	1.31
Beta (2Y)	1.26
Change from 52-week high	-52.75%
Change from 52-week low	10.83%
Change from all-time high	-77%
Change from all-time low	6.7%
Change from open	0.23%
Day's gap	6.72%
Dollar volume	$93,297
High price	$4.30
Low price	$4.29
Monthly RSI	11.75
Open price	$4.29
Position in 52-week range	100%
Previous close	$4.02
Price vs 150-day SMA	-22.69%
Price vs 20-day SMA	-2.59%
Price vs 200-day SMA	-26.82%
Price vs 50-day SMA	-12.46%
Relative volume	1.56
RSI	39.87
Sharpe ratio	-1.02
Sortino ratio	-1.42
Volume	21.7K
Weekly RSI	30.94
YTD price change	-40%
YTD total return	-40%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5.8M
Float percentage	51.4%
Shares change (QoQ)	44.16%
Shares change (YoY)	-97.61%
Shares held by insiders	2.06%
Shares held by institutions	27.86%
Shares outstanding	11.4M
Short % of float	0.56%
Short % of shares	0.29%
Short ratio	1.9 days

Deeper analysis on IMA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this IMA report

Is a complete IMA research report available?

No complete published report is available for ImageneBio, Inc. (IMA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ImageneBio, Inc. (IMA)

Price

Financial snapshot

Fair-value bridge

Latest news · IMA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IMA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on IMA

Frequently asked questions